A birth cohort analysis of the incidence of adenocarcinoma of the uterine cervix in the USA

European Journal of Cancer Prevention

Volumn 24, Issue 3, 2015, Pages 240-244

  Zhu, Cairong ^a,c   Bassig, Bryan A ^c   Zhang, Yawei ^c   Shi, Kunchong ^c   Boyle, Peter ^d   Li, Ni ^b,c   Zheng, Tongzhang ^c  

^a SICHUAN UNIVERSITY   (China)

^b CANCER HOSPITAL   (China)

^c YALE UNIVERSITY   (United States)

^d INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

Author keywords

adenocarcinoma; age period cohort effect; cervical cancer; diethylstilbestrol use; incidence rate

Indexed keywords

DIETHYLSTILBESTROL; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BIRTH; CANCER INCIDENCE; CANCER RISK; CAUCASIAN; COHORT ANALYSIS; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; OBESITY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RACE DIFFERENCE; UNITED STATES; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX CARCINOMA; ADENOCARCINOMA; CANCER REGISTRY; CHEMICALLY INDUCED; INCIDENCE; PREGNANCY; RISK FACTOR; TRENDS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

ADENOCARCINOMA; ADULT; COHORT STUDIES; DIETHYLSTILBESTROL; FEMALE; HUMANS; INCIDENCE; PREGNANCY; RISK FACTORS; SEER PROGRAM; UNITED STATES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84926417968     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000062     Document Type: Article

References (35)

1. [No authors listed] (1976). Exposure in utero to diethylstilbestrol and related synthetic hormones. Association with vaginal and cervical cancers and other abnormalities. JAMA 236:1107-1109.
2. Adegoke O, Kulasingam S, Virnig B (2012). Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health (Larchmt) 21:1031-1037.
3. Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, Goodhill A, et al. International Collaboration of Epidemiological Studies of Cervical Cancer (2007). Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies. Lancet 370:1609-1621.
4. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002). The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55:244-265.
5. Boyd J, Takahashi H, Waggoner SE, Jones LA, Hajek RA, Wharton JT, et al. (1996). Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero. Cancer 77:507-513.
6. Castellsague X, Diaz M, de Sanjose S, Muñoz N, Herrero R, Franceschi S, et al. (2006). Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98:303-315.
7. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL (1998). Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 22:39-47.
8. Flegal KM, Carroll MD, Ogden CL, Johnson CL (2002). Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288:1723-1727.
9. Flegal KM, Carroll MD, Kit BK, Ogden CL (2012). Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 307:491-497.
10. Giusti RM, Iwamoto K, Hatch EE (1995). Diethylstilbestrol revisited: a review of the long-term health effects. Ann Intern Med 122:778-788.
11. Green J, Berrington de Gonzalez A, Sweetland S, Beral V, Chilvers C, Crossley B, et al. (2003). Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20-44 years: the UK National Case-Control Study of Cervical Cancer. Br J Cancer 89:2078-2086.
12. Hatch EE, Palmer JR, Titus-Ernstoff L, Noller KL, Kaufman RH, Mittendorf R, et al. (1998). Cancer risk in women exposed to diethylstilbestrol in utero. JAMA 280:630-634.
13. Herbst AL, Ulfelder H, Poskanzer DC (1971). Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 284:878-881.
14. Holford TR (2003). Monitoring the health of population: Statistical principles and methods for public health surveillance. Oxford: Oxford Univerity Press.
15. IARC (2012). Diethylstilbestrol. Lyon: IARC.
16. Jones J, Mosher W, Daniels K. Division of Vital Statistics (2012). Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995. Natl Health Stat Rep No. 60.
17. Lacey JV Jr, Swanson CA, Brinton LA, Altekruse SF, Barnes WA, Gravitt PE, et al. (2003). Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer 98:814-821.
18. Laronda MM, Unno K, Butler LM, Kurita T (2012). The development of cervical and vaginal adenosis as a result of diethylstilbestrol exposure in utero. Differentiation 84:252-260.
19. Liu S, Semenciw R, Mao Y (2001). Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ 164:1151-1152.
20. Madeleine MM, Daling JR, Schwartz SM, Shera K, McKnight B, Carter JJ, et al. (2001). Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prev 10:171-177.
21. Mathew A, George PS (2009). Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix-worldwide. Asian Pac J Cancer Prev 10:645-650.
22. Mosher WD, Jones JJ (2010). Use of contraception in the United States: 1982-2008. Vital Health Stat 2329:1-44.
23. NCI (2011). Fact Sheet Human Papillomavirus (HPV) vaccines.
24. NCI (2014). DES exposure: questions and answers.
25. Reimers LL, Anderson WF, Rosenberg PS, Henson DE, Castle PE (2009). Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-period-cohort models. Cancer Epidemiol Biomarkers Prev 18:792-800.
26. Simard EP, Naishadham D, Saslow D, Jemal A (2012). Age-specific trends in black-white disparities in cervical cancer incidence in the United States: 1975-2009. Gynecol Oncol 127:611-615.
27. Smith EK, White MC, Weir HK, Peipins LA, Thompson TD (2012). Higher incidence of clear cell adenocarcinoma of the cervix and vagina among women born between 1947 and 1971 in the United States. Cancer Causes Control 23:207-211.
28. Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M, et al. (2003). Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361:1159-1167.
29. Townsend DE (1996). Primary non-clear cell adenocarcinoma of the vagina in older DES-exposed women. Gynecol Oncol 61:454.
30. Vaccarella S, Herrero R, Dai M, Snijders PJF, Meijer CJ, Thomas JO, et al. (2006). Reproductive factors, oral contraceptive use, and human papillomavirus infection: Pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 15:2148-2153.
31. Visioli CB, Zappa M, Ciatto S, Iossa A, Crocetti E (2004). Increasing trends of cervical adenocarcinoma incidence in Central Italy despite extensive screening programme, 1985-2000. Cancer Detect Prev 28:461-464.
32. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
33. Wang SS, Sherman ME, Hildesheim A, Lacey JV Jr, Devesa S (2004). Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 100:1035-1044.
34. Waxman AG (2005). Guidelines for cervical cancer screening: history and scientific rationale. Clin Obstet Gynecol 48:77-97.
35. Zheng T, Holford TR, Ma Z, Chen Y, Liu W, Ward BA, Boyle P (1996). The continuing increase in adenocarcinoma of the uterine cervix: a birth cohort phenomenon. Int J Epidemiol 25:252-258.